Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
MEZLIN (mezlocillin sodium monohydrate) is an injectable broad-spectrum penicillin antibiotic approved in 1981 for treating bacterial infections. It works by inhibiting bacterial cell wall synthesis and is administered via injection for systemic infections. The drug is indicated for serious gram-positive and gram-negative bacterial infections.
As an approaching LOE injectable with moderate competitive pressure (30), the brand team is likely in transition planning mode with reduced headcount and focus shifting toward managed care and hospital formulary management rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
MEZLIN offers limited career growth opportunities given its approaching LOE status and zero linked job openings; roles are primarily defensive and focused on maximizing remaining patent life and hospital formulary placement. Working on this product involves mature-market expertise in generic erosion, hospital contracting, and cost-containment strategy rather than innovation or launch activities.
Worked on MEZLIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.